Search results for: Downs
Change Creates Opportunity with Ramin Valian
PODCAST EPISODE 303
Read MoreOIS Retina@ASRS Sizes Up the Challenges in Retina Innovation
The first live OIS program in almost two years, OIS Retina@ASRS, was as much an update on what was portrayed as a robust innovation ecosystem directed at the treatment and diagnosis of retinal disease as much as it was about how the space has fared through the COVID-19 pandemic. But it also provided insights into…
Read MoreOIS Retina@ASRS Brings Retina Leaders Together (Again) for Live Meeting in San Antonio
The live and in-person summit showcasing innovation in retina, OIS Retina@ASRS, will be held in San Antonio, Texas, on October 7, a day before the annual meeting of the American Society of Retina Specialists opens. It will be the first live OIS meeting since 2019. The conference provides a nexus for stakeholders in retina product…
Read MoreRetina ASRS 2021 Agenda
HomeRetina ASRS 2021 AgendaSpeakersPresenting CompaniesVenueCOVID PolicyConference Day AGENDA | OCTOBER 7 time reflects central standard time 7:30 – 8:30 AM Check-in & Networking Breakfast 8:30 – 8:40 AM Opening & Hot Topics in the Retina Space Presented By: Firas M. Rahhal, MD, Partner – ExSight Ventures & Retina Vitreous Associates Medical Group 8:40 – 8:55…
Read MoreDeveloping a Clear Vision for a Clinical-Stage Company with Ben Bergo
PODCAST EPISODE 291
Read MoreBuilding a Best-in-Class Company for a Best-in-Class Therapy: LENZ Therapeutics CEO Eef Schimmelpennink
PODCAST EPISODE 290
Read MoreEarning the Right to Ask for the Business with Nick Curtis of LENSAR
PODCAST EPISODE 278
Read MoreGyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA
Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is being evaluated for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GT005 also received Fast Track designation from the Food and Drug Administration for the treatment of…
Read MoreBuilding Value for Pipeline Assets with Mina Sooch
PODCAST EPISODE 275
Read MoreOsmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary
Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution, Osmotica Pharmaceuticals‘ Upneeq (oxymetazoline hydrochloride 0.1%, formerly known as RVL-1201), is a first-in-class agent and the only approved drug indicated for droopy upper eyelids, which can interfere with patients’ field…
Read MoreThe Time is Nau!
PODCAST EPISODE 238 Click here to watch the video version of this podcast. Host Ehsan Sadri, MD, is joined by Jeffrey Nau, PhD, who shares insights from a career in ophthalmology that has led to his current role as the CEO of publicly traded Oyster Point Pharma. In this interview, Jeff addresses some of the…
Read MoreOrasis CEO and Chairman Share Their Strategies for Success
PODCAST EPISODE 230 Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology…
Read More